Stay updated with breaking news from Surgical Replacement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and...
Press release content from PR Newswire. The AP news staff was not involved in its creation.
TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years
TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years Medtronic plc a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation Trial, which was presented as a Late Breaking Clinical Trial at the 33 rd Transcatheter Cardiovascular Therapeutics conference, the ...
Medtronic Evolut TAVI Now Licensed for Both Bicuspid Aortic Valves at Intermediate or Greater Risk and for Low Risk of Surgical Mortality Health Canada Issues Licence for Expanded Indications for Evolut TAVI Platform Medtronic Canada ULC, a subsidiary of Medtronic plc ― the world’s largest medical technology, services, and solutions company ― has received a new expanded indication from Health Canada for its Evolut™ Transcatheter Aortic Valve Implantation system. Medtronic’s TAVI platform is currently the only system licensed for both bicuspid … Health Canada Issues Licence for ...